NCT06021366

Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,089 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

REALIZE was a single-arm retrospective cohort study which described treatment patterns with brolucizumab, including treatment intervals between anti-vascular endothelial growth factor (VEGF) injections before and after a switch to brolucizumab. This study was conducted using German patient-level prescription data and the prescription date was used as a proxy for anti-VEGF injection date. The study period was defined from the date of the first available anti-VEGF injection in the dataset to 30 November 2021. The index date for each patient was the date of the first brolucizumab injection, which could be anytime between 01 March 2020 (since brolucizumab became available in Germany for use outside of clinical trials in March 2020) and 30 November 2021. The date of the patient's first neovascular age-related macular degeneration (nAMD) diagnosis was assumed to be the date of the first anti-VEGF prescription in the database for that patient, from January 2015 onwards.

Conditions

• Neovascular Age-related Macular Degeneration

Timeline

• Start date: 2022-01-07
• Primary completion: 2022-08-29
• Completion: 2022-08-29
• First posted: 2023-09-01
• Last updated: 2023-09-01

Locations

1 site across 1 country: Portugal